Silence Therapeutics plc (NASDAQ:SLN) Receives $57.20 Consensus Target Price from Analysts

Shares of Silence Therapeutics plc (NASDAQ:SLN) have been assigned a consensus rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have issued a report on the stock in the last year is $57.20.

SLN has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Friday, November 15th. Morgan Stanley reiterated an “overweight” rating and issued a $49.00 price target on shares of Silence Therapeutics in a report on Tuesday, October 8th. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday. Chardan Capital reiterated a “buy” rating and issued a $55.00 price target on shares of Silence Therapeutics in a report on Thursday, November 14th. Finally, Jefferies Financial Group initiated coverage on shares of Silence Therapeutics in a report on Tuesday, September 3rd. They set a “buy” rating and a $40.00 target price for the company.

Silence Therapeutics Stock Performance

Shares of NASDAQ:SLN opened at $7.68 on Tuesday. Silence Therapeutics has a 52 week low of $5.81 and a 52 week high of $27.72. The company has a market capitalization of $229.86 million, a PE ratio of -4.89 and a beta of 1.30. The company has a 50 day moving average price of $17.13 and a two-hundred day moving average price of $18.78.

Institutional Trading of Silence Therapeutics

Several hedge funds have recently bought and sold shares of the business. Values First Advisors Inc. acquired a new stake in Silence Therapeutics in the 3rd quarter valued at $56,000. Quarry LP purchased a new position in Silence Therapeutics during the 2nd quarter worth $114,000. SG Americas Securities LLC boosted its holdings in Silence Therapeutics by 10.5% during the 1st quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock worth $151,000 after acquiring an additional 667 shares during the last quarter. Verition Fund Management LLC purchased a new position in Silence Therapeutics during the 3rd quarter worth $207,000. Finally, Custom Index Systems LLC purchased a new position in Silence Therapeutics during the 2nd quarter worth $282,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.